Related Experiment Video

Updated: Jan 20, 2026

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

905

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated

Natalie Prinzi1, Alessandra Raimondi1, Marco Maccauro1

  • 1Fondazione IRCCS Istituto Nazionale Tumori Milano, ENETS Center of Excellence, Department of Medical Oncology, Milan, Italy.

Future Oncology (London, England)
|August 20, 2019
PubMed

Insights

Switching somatostatin analogs (SSAs) after progression in patients with advanced gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy improves survival outcomes. This strategy offers better progression-free and overall survival compared to maintaining the same SSA treatment.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Endocrinology

Background:

  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies.
  • Peptide receptor radionucleotide therapy (PRRT) combined with somatostatin analogs (SSAs) is a standard treatment for advanced GEP-NETs.
  • Treatment failure with SSAs necessitates evaluating alternative therapeutic strategies.

Purpose of the Study:

  • To evaluate the impact of switching somatostatin analogs (SSAs) versus continuing the same SSA after disease progression in patients with advanced well-differentiated GEP-NETs undergoing PRRT.
  • To compare progression-free survival (PFS) and overall survival (OS) between the two treatment strategies.

Main Methods:

  • Retrospective analysis of 69 patients with well-differentiated GEP-NETs treated with PRRT and SSAs.
  • Patients were divided into two groups: S1 (maintained same SSA after progression) and S2 (switched to a different SSA after progression).
  • Progression-free survival and overall survival were the primary endpoints.

Main Results:

  • Median PFS was significantly longer in the switch group (S2: 127 months) compared to the maintain group (S1: 53 months) (p=0.001).
  • Median OS was also significantly improved in the switch group (S2: 150 months) versus the maintain group (S1: 69 months) (p=0.004).
  • Hazard ratios indicated a substantially lower risk of progression and death in the switch group.

Conclusions:

  • Switching to a different somatostatin analog after disease progression, in combination with PRRT, significantly improves both progression-free and overall survival in patients with advanced well-differentiated GEP-NETs.
  • The 'switch' strategy represents a more effective approach compared to continuing the same SSA after progression.
  • This finding supports personalized treatment adjustments in managing advanced GEP-NETs.
Keywords:
combinational therapygasto-entero-pancreatic neuroendocrine tumorspeptide receptor radionucleotide therapysomatostatin analoguesswitching strategy

More Related Videos

Simplified Human Neutrophil Extracellular Traps NETs Isolation and Handling09:43

Simplified Human Neutrophil Extracellular Traps NETs Isolation and Handling

Published on: April 16, 2015

31.4K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.4K

Related Concept Videos

Peptide Bonds02:43

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.4K
Association Areas of the Cortex01:21

Association Areas of the Cortex

Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
9.0K
Associative Learning01:27

Associative Learning

Associative learning is a fundamental concept in behavioral psychology, wherein a connection is established between two stimuli or events, leading to a learned response. This process is critical in understanding how behaviors are acquired and modified. Conditioning, the mechanism through which associations are formed, can be divided into two main types: classical conditioning and operant conditioning, each elucidating different aspects of associative learning.
Classical conditioning, also known...
1.3K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.3K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
110.6K